富马酸喹硫平对精神分裂症急性期阴性症状和抑郁症状的疗效研究

来源 :2014中华医学会第十二次全国精神医学学术会议 | 被引量 : 0次 | 上传用户：BeginJava123

【摘要】

：

目的评价富马酸喹硫平单药治疗精神分裂症急性期阴性症状和抑郁症状的疗效.方法采用前瞻性、单组、开放性的研究设计.纳入符合ICD-10精神分裂症诊断标准的124例精神分裂症急性期住院患者,予富马酸喹硫平600～750mg/d单药治疗,观察时间为24周,在基线、治疗第1周末、第8周末及第24周末评估患者的治疗效果及安全性.疗效指标为阳性与阴性症状综合征量表(PANSS)评分变化、蒙哥马利抑郁量表(M

【作者】

：

耿莹胡昌清陈静曹至进王刚肖乐

【机构】

：

首都医科大学附属北京安定医院北京市怀柔安佳医院

【出处】

：

2014中华医学会第十二次全国精神医学学术会议

【发表日期】

：

2014年3期

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

其他文献

Emergent activation other than cardiologist activation is associated with process improvement in the

Background To evaluate the effect of emergent activation on the process of primary percutaneous coronary intervention (PCI) in the care of ST segment elevated myocardial infarction(STEMI) patients.Met

会议

Bifurcation lesions using mini culotte treatment can improve the rate of expansion eventually kissin

Background Bifurcation lesions double stenting whether or not to complete the kiss expansion directly influences the prognosis,the final kissing rate of classical CRUSH technique is low,DK crush techn

会议

Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of

Background It remains unclear whether intracoronary (IC) or intravenous (Ⅳ) administration of Tirofiban is superior for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary int

会议

Expression of microRNA-155 and microRNA-146a in peripheral blood mononuclear cells correlates with a

Background MicroRNA (miRNA) is a newly discovered endogenous non-coding single stranded RNAs,composed of 20-23 nucleotides,plays an important role in regulating in the process of cell differentiation,

会议

Performance of 2.25-mm diameter FIREHAWK abluminal groove-filled biodegradable polymer sirolimus-elu

Background Higher rates of adverse cardiac events and restenosis have been observed in patients with small vessel disease.The workhorse sizes of FIREHAWK abluminal groove-filled biodegradable polymer

会议

One-year results of everolimus-eluting stents for treatment of long coronary lesions:a subgroup anal

Background Long coronary lesions remain a higher risk of unfavorable outcomes after percutaneous coronary intervention and the stent length was recognized an independent factor for DES failure.No larg

会议

One-year results of everolimus-eluting stents for treatment of multivessel disease:a subgroup analys

Background The choice of revascularization strategy in multivessel coronary disease remains a critical issue in cardiology.No large-scale clinical study of everolimus-eluting Stents (EES) was conducte

会议

Impact of diabetes status on long-term (6 years) outcomes after percutaneous coronary intervention o

Background Scant data exist regarding the impact of diabetes mellitus (DM) status on percutaneous coronary intervention (PCI) for left main (LM) coronary artery disease.We sought to compare the impact

会议

Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent

Background TARGET Ⅰ randomized controlled trial (RCT) demonstrated that the novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent FIREHAWK (MicroPort Medical,Shanghai,China) was

会议

富马酸喹硫平对精神分裂症急性期兴奋症状疗效的研究

目的评价富马酸喹硫平600 ～ 750mg/d单药治疗精神分裂症急性期兴奋症状的疗效和安全性.方法采用前瞻性、单组、开放性的设计,纳入符合ICD-10诊断标准的精神分裂症急性期患者124例,予喹硫平600～750mg/d单药治疗.观察时间为24周,在基线、治疗第1周末、第8周末及第24周末评估患者的治疗效果及安全性.疗效指标为阳性与阴性症状综合症量表(positive and negative

会议

富马酸喹硫平对精神分裂症急性期阴性症状和抑郁症状的疗效研究

与本文相关的学术论文